The Effects of New Antidiabetic Drugs on the Course of Peripheral Arterial Occlusive Disease
Abstract
Background: Peripheral arterial occlusive disease (PAOD) and diabetic foot syndrome (DFS) are the leading reasons for lower-limb amputation. The new antidiabetic drugs-GLP-1 receptor agonists (GLP-1-RA) and SGLT-2 inhibitors (SGLT-2-I)-improve glycemic control and lower the risk of cardiovascular events. The differing effects of these two drug classes on PAOD are currently under discussion.
Methods: This narrative review is based on pertinent publications retrieved by a selective PubMed search employing the terms "peripheral arterial disease," "SGLT-2 inhibitors," and "GLP-1 receptor agonists."
Results: No randomized controlled trials (RCTs) of the use of SGLT-2 inhibitors and GLP-1 receptor agonists have yet been conducted in which amputation served as a primary endpoint; in the published trials, amputation is reported only as an adverse event. The SGLT-2 inhibitors empagliflozin and dapagliflozin, which are approved in Germany, were not associated with a significantly increased risk of amputation in RCTs. In one RCT, the GLP-1 receptor agonist semaglutide led to a median prolongation of maximum walking distance by 26.4 m in patients with PAOD. Evidence suggests that GLP-1 receptor agonists may improve the clinical course of PAOD.
Conclusion: The available evidence concerning the effect of GLP-1 receptor agonists and SGLT-2 inhibitors on the course of peripheral arterial occlusive disease (PAOD) and diabetic foot syndrome is limited. At any rate, no evidence suggests that…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.